Biotechnology company focused on epigenomic programming to treat and cure genetic diseases.
Omega Therapeutics, Inc. is a clinical-stage biotechnology firm headquartered in Cambridge, Massachusetts, specializing in innovative epigenomic therapies. The company leverages its OMEGA Epigenomic Programming platform to harness the power of epigenetics, the mechanism that regulates gene expression across an organism's lifecycle.
Central to Omega Therapeutics' approach is the ability to modulate fundamental epigenetic processes. This platform aims to address the root causes of diseases by restoring aberrant gene expression to normal levels, without altering the native DNA sequence. The company's mRNA medicines and Omega Epigenomic Controllers are designed with modularity and programmability to target specific epigenomic loci within insulated genomic domains, offering potential therapies for a wide spectrum of diseases through Precision Genomic Control.
Omega Therapeutics is actively advancing a robust pipeline of development candidates across diverse therapeutic areas. These include oncology, regenerative medicine, multigenic diseases, and select monogenic diseases. Each candidate is strategically designed to leverage the precise targeting capabilities of the OMEGA platform, aiming to bring transformative treatments and potential cures to patients in need.
Founded in 2016, Omega Therapeutics continues to expand its pioneering efforts in epigenomic medicine. With a commitment to scientific innovation and therapeutic precision, the company is poised to make significant strides in reshaping the landscape of healthcare through advanced genomic technologies.